2023
Aiming for the cure in myeloma: Putting our best foot forward
Bar N, Firestone R, Usmani S. Aiming for the cure in myeloma: Putting our best foot forward. Blood Reviews 2023, 62: 101116. PMID: 37596172, DOI: 10.1016/j.blre.2023.101116.Peer-Reviewed Original ResearchConceptsMultiple myelomaMinimal residual disease negativityDeeper response ratesResponse-adapted strategyDuration of therapyPowerful prognostic factorSignificant inter-patient variabilityNovel clinical trialsInter-patient variabilityRegimen compositionFrontline therapyUpfront therapyPrognostic factorsMyeloma patientsMyeloma treatmentClinical trialsTreatment strategiesCurrent relevant literatureTreatment approachesResponse rateDisease riskTherapyMyelomaUse of transplantsCurrent standardOutcomes of intraventricular 131-I-omburtamab and external beam radiotherapy in patients with recurrent medulloblastoma and ependymoma
Tringale K, Wolden S, Karajannis M, Haque S, Pasquini L, Yildirim O, Rosenblum M, Benhamida J, Cheung N, Souweidane M, Basu E, Pandit-Taskar N, Zanzonico P, Humm J, Kramer K. Outcomes of intraventricular 131-I-omburtamab and external beam radiotherapy in patients with recurrent medulloblastoma and ependymoma. Journal Of Neuro-Oncology 2023, 162: 69-78. PMID: 36853490, PMCID: PMC10050019, DOI: 10.1007/s11060-022-04235-w.Peer-Reviewed Original ResearchConceptsExternal beam radiotherapyCompartmental radioimmunotherapyOverall survivalCraniospinal axisBeam radiotherapyRecurrent medulloblastomaCases of radiation necrosisAssociated with progression-freeRecurrent primary brain tumorsCases of radionecrosisImprove survival outcomesMedium follow-upProspective clinical trialKaplan-Meier analysisPredictors of responseExtent of diseasePatterns of failurePrimary brain tumorNED statusUpfront therapyProgression-FreeRadiation necrosisConclusionFor patientsEpendymoma patientsMultimodal therapy
2022
Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance
Schoenfeld D, Merkin R, Moutafi M, Martinez S, Adeniran A, Kumar D, Jilaveanu L, Hurwitz M, Rimm D, Kluger H. Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance. Frontiers In Oncology 2022, 12: 990367. PMID: 36313654, PMCID: PMC9608089, DOI: 10.3389/fonc.2022.990367.Peer-Reviewed Original ResearchRenal cell carcinomaImmune checkpoint inhibitorsMetastatic sitesBrain metastasesPrimary tumorMechanisms of resistancePD-1/PD-L1Anti-PD-1 therapyHigh-risk clinical characteristicsLarger primary tumor sizeAdvanced renal cell carcinomaAlternative immune checkpointsCertain drug regimensPoor-risk diseasePD-1 inhibitorsMinority of patientsPrimary tumor sizeLonger overall survivalGrade 4 tumorsProtein levelsPrimary RCC tumorsAttractive therapeutic targetIdentification of subgroupsCheckpoint inhibitorsUpfront therapy
2020
Overall Survival of CDK4/6-Inhibitor–Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis
Schettini F, Giudici F, Giuliano M, Cristofanilli M, Arpino G, Del Mastro L, Puglisi F, De Placido S, Paris I, De Placido P, Venturini S, De Laurentis M, Conte P, Juric D, Llombart-Cussac A, Pusztai L, Prat A, Jerusalem G, Di Leo A, Generali D. Overall Survival of CDK4/6-Inhibitor–Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis. Journal Of The National Cancer Institute 2020, 112: 1089-1097. PMID: 32407488, PMCID: PMC7669227, DOI: 10.1093/jnci/djaa071.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6FemaleHumansLetrozoleNeoplasm MetastasisPiperazinesProtein Kinase InhibitorsPyridinesRandomized Controlled Trials as TopicConceptsSecond-line therapyMetastatic breast cancerEndocrine therapyCDK4/6 inhibitorsVisceral involvementBreast cancerPostmenopausal metastatic breast cancerAvailable phase IIChemotherapy-naïve patientsClear OS benefitSpecific clinical subgroupsProgression-free survivalOverall survival dataBreast cancer prognosisStudy-level factorsCyclin-dependent kinase 4Random-effects modelSystematic literature searchEndocrine monotherapyOS benefitOS independentOverall survivalUpfront therapyMenopausal statusMetastatic sites
2018
Treatment of newly diagnosed primary central nervous system lymphoma: current and emerging therapies
Sethi TK, Reddy NM. Treatment of newly diagnosed primary central nervous system lymphoma: current and emerging therapies. Leukemia & Lymphoma 2018, 60: 6-18. PMID: 29741421, DOI: 10.1080/10428194.2018.1466296.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAge FactorsAgedAntineoplastic Combined Chemotherapy ProtocolsBiopsyBone MarrowBrainCentral Nervous System NeoplasmsChemoradiotherapyCognitive DysfunctionCranial IrradiationFemaleHumansLymphoma, Large B-Cell, DiffuseMagnetic Resonance ImagingMiddle AgedNeoplasm Recurrence, LocalPrognosisProgression-Free SurvivalRemission InductionStem Cell TransplantationTransplantation, AutologousConceptsPrimary central nervous lymphomaDiffuse large B-cell lymphoma histologyPrimary central nervous system lymphomaAutologous stem cell transplantCentral nervous system lymphomaMulti-agent chemotherapyNervous system lymphomaStem cell transplantNon-Hodgkin lymphomaLong-term toxicityEligible patientsImmunotherapy optionsRelapsed diseaseAggressive presentationUpfront therapySystem lymphomaCell transplantFrontline treatmentPathogenetic pathwaysLymphoma histologyCurrent evidenceFrontline strategyLymphomaTherapyOngoing studies
2010
Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide
Kaloshi G, Sierra del Rio M, Ducray F, Psimaras D, Idbaih A, Laigle-Donadey F, Taillibert S, Houillier C, Dehais C, Omuro A, Sanson M, Delattre JY, Hoang-Xuan K. Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide. Journal Of Neuro-Oncology 2010, 100: 439-441. PMID: 20464625, DOI: 10.1007/s11060-010-0197-6.Peer-Reviewed Original ResearchConceptsLow-grade gliomasGrade gliomasProgressive low-grade gliomaTerms of PFSContrast enhancementEfficacy of nitrosoureasBetter PFSMedian PFSMedian OSObjective responseSalvage treatmentUpfront therapyMedian ageBetter prognosisInitial treatmentConventional radiotherapyChromosome 1p/19q codeletionNon-enhancing tumorResponse ratePatientsTemozolomidePure oligodendrogliomasPFSGliomasDisappointing results
2006
Aromatase Inhibitors in the Adjuvant Treatment of Postmenopausal Women with Early Stage Breast Cancer
Ligibel JA, Winer EP. Aromatase Inhibitors in the Adjuvant Treatment of Postmenopausal Women with Early Stage Breast Cancer. Women's Health 2006, 2: 89-97. PMID: 19803930, DOI: 10.2217/17455057.2.1.89.Peer-Reviewed Original Research
2005
Aromatase inhibitors as adjuvant therapy for postmenopausal women: a therapeutic advance but many unresolved questions
Ligibel JA, Winer EP. Aromatase inhibitors as adjuvant therapy for postmenopausal women: a therapeutic advance but many unresolved questions. Breast Cancer Research 2005, 7: 255. PMID: 16457700, PMCID: PMC1410766, DOI: 10.1186/bcr1347.Peer-Reviewed Original ResearchConceptsAromatase inhibitorsPostmenopausal womenEarly-stage breast cancerCourse of tamoxifenAdjuvant hormonal therapyStage breast cancerAdjuvant settingAdjuvant therapyHormonal therapyUpfront therapyOngoing trialsMajor trialsTherapeutic advancesBreast cancerTherapyInhibitorsTrialsWomenTamoxifenYearsCancer
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply